JLL vs PTGX · P/E 23, rev $13.31B vs rev $269.8M
Jones Lang LaSalle Incorporated (JLL) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported JLL revenue for 2026-06-30 was $13.31B. Net income was $373.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the JLL and PTGX stock pages for the full models.
Not investment advice.